Jens Ricke1, Christoph Benedikt Westphalen2, Max Seidensticker1. 1. Klinik und Poliklinik für Radiologie, LMU Klinikum, Munich, Germany. 2. Medizinische Klinik und Poliklinik III und CCC München, Klinikum der Universität München, LMU München, Munich, Germany.
Abstract
BACKGROUND: Clinical trials have proven a survival benefit from applying local therapies for oligometastatic cancers of various origin. SUMMARY: Today, the definition of oligometa-static disease is based on limited lesion numbers and organ systems involved. Treatment guidelines by the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO) and several other groups suggest a threshold of up to 5 tumours. Established biological markers indicating the aggressiveness of a given tumour (and therefore suggesting local treatment only or the addition of or complete switch to systemic therapies) are missing, except for disease-free survival, the only recommended parameter for patient selection beyond lesion count. KEY MESSAGE: The following article discusses clinical implications as well as local techniques established for the treatment of oligometastatic disease.
BACKGROUND: Clinical trials have proven a survival benefit from applying local therapies for oligometastatic cancers of various origin. SUMMARY: Today, the definition of oligometa-static disease is based on limited lesion numbers and organ systems involved. Treatment guidelines by the European Organisation for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO) and several other groups suggest a threshold of up to 5 tumours. Established biological markers indicating the aggressiveness of a given tumour (and therefore suggesting local treatment only or the addition of or complete switch to systemic therapies) are missing, except for disease-free survival, the only recommended parameter for patient selection beyond lesion count. KEY MESSAGE: The following article discusses clinical implications as well as local techniques established for the treatment of oligometastatic disease.
Authors: George J Arnaoutakis; Deepa Rangachari; Daniel A Laheru; Chris A Iacobuzio-Donahue; Ralph H Hruban; Joseph M Herman; Barish H Edil; Timothy M Pawlik; Richard D Schulick; John L Cameron; Avedis Meneshian; Stephen C Yang; Christopher L Wolfgang Journal: J Gastrointest Surg Date: 2011-07-02 Impact factor: 3.452
Authors: David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan Journal: Lancet Date: 2019-04-11 Impact factor: 79.321
Authors: René Adam; Robbert J de Haas; Dennis A Wicherts; Thomas A Aloia; Valérie Delvart; Daniel Azoulay; Henri Bismuth; Denis Castaing Journal: J Clin Oncol Date: 2008-08-01 Impact factor: 44.544
Authors: Stephan Kruger; Michael Haas; Philipp Johannes Burger; Steffen Ormanns; Dominik Paul Modest; Christoph Benedikt Westphalen; Marlies Michl; Axel Kleespies; Martin Kurt Angele; Werner Hartwig; Christiane Josephine Bruns; Maximilian Niyazi; Falk Roeder; Thomas Kirchner; Jens Werner; Volker Heinemann; Stefan Boeck Journal: Pancreatology Date: 2016-03-30 Impact factor: 3.996
Authors: Ricarda Seidensticker; Robert Damm; Julia Enge; Max Seidensticker; Konrad Mohnike; Maciej Pech; Peter Hass; Holger Amthauer; Jens Ricke Journal: BMC Cancer Date: 2018-09-10 Impact factor: 4.430
Authors: Hamid Nikbakht; Selin Jessa; Mahadeo A Sukhai; Madeleine Arseneault; Tong Zhang; Louis Letourneau; Mariam Thomas; Mathieu Bourgey; Michael H A Roehrl; Robert Eveleigh; Eric X Chen; Monika Krzyzanowska; Malcolm J Moore; Amanda Giesler; Celeste Yu; Philippe L Bedard; Suzanne Kamel-Reid; Jacek Majewski; Lillian L Siu; Yasser Riazalhosseini; Donna M Graham Journal: Sci Rep Date: 2020-01-17 Impact factor: 4.379
Authors: Matthias F Froelich; Moritz L Schnitzer; Nils Rathmann; Fabian Tollens; Marcus Unterrainer; Shereen Rennebaum; Max Seidensticker; Jens Ricke; Johannes Rübenthaler; Wolfgang G Kunz Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639